Skip to main content
NCD 190.15 · version 1 · Laboratory NCD

NCD 190.15: Blood Counts

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database NCDs: API snapshot September 27, 2026 (effective September 20, 2026); Lab NCD code lists: October 2026 (effective October 1, 2026). Next CMS release: weekly, every Thursday for the Medicare Coverage Database NCDs; January 1, 2027 (quarterly update) for the Lab NCD code lists.

Medicare Coverage Database NCDs: the loaded version is API snapshot September 27, 2026, and the CMS schedule called for a newer one from October 1, 2026. Verify figures against the current CMS publication until this reference is rebuilt; pages built on it are withdrawn from search indexing until then.

Key facts for NCD 190.15

Benefit category
Diagnostic Laboratory Tests
Effective date
11/25/2002
Implemented 01/01/2003
Transmittal
Transmittal 17
Versions published
1
Manual section
190
Pathology and Laboratory, NCD Manual (Pub. 100-03) chapter 1 part 3
Lab edit list
Unlisted ICD-10 covered
22,258 listed codes not supported, 233 non-covered

TL;DR

NCD 190.15 sets Medicare's national policy for blood counts under the benefit category "Diagnostic Laboratory Tests", effective 11/25/2002 and implemented 01/01/2003. Indications for a CBC or hemogram include red cell, platelet, and white cell disorders. Examples of these indications are enumerated individually below. As a laboratory NCD it carries a national ICD-10 edit list that works by exclusion: any diagnosis code not on the list supports medical necessity, while 22,258 listed codes do not and 233 are denied, applied automatically by every Medicare contractor to 11 procedure codes.

Item or service described

Blood counts are used to evaluate and diagnose diseases relating to abnormalities of the blood or bone marrow. These include primary disorders such as anemia, leukemia, polycythemia, thrombocytosis and thrombocytopenia. Many other conditions secondarily affect the blood or bone marrow, including reaction to inflammation and infections, coagulopathies, neoplasms and exposure to toxic substances. Many treatments and therapies affect the blood or bone marrow, and blood counts may be used to monitor treatment effects.

The complete blood count (CBC) includes a hemogram and differential white blood count (WBC). The hemogram includes enumeration of red blood cells, white blood cells, and platelets, as well as the determination of hemoglobin, hematocrit, and indices.

The symptoms of hematological disorders are often nonspecific, and are commonly encountered in patients who may or may not prove to have a disorder of the blood or bone marrow. Furthermore, many medical conditions that are not primarily due to abnormalities of blood or bone marrow may have hematological manifestations that result from the disease or its treatment. As a result, the CBC is one of the most commonly indicated laboratory tests.

Inpatients with possible hematological abnormalities, it may be necessary to determine the hemoglobin and hematocrit, to calculate the red cell indices, and to measure the concentration of white blood cells and platelets. These measurements are usually performed on a multichannel analyzer that measures all of the parameters on every sample. Therefore, laboratory assessments routinely include these measurements.

Indications and limitations of coverage

Indications

Indications for a CBC or hemogram include red cell, platelet, and white cell disorders. Examples of these indications are enumerated individually below.

• Indications for a CBC generally include the evaluation of bone marrow dysfunction as a result of neoplasms, therapeutic agents, exposure to toxic substances, or pregnancy. The CBC is also useful in assessing peripheral destruction of blood cells, suspected bone marrow failure or bone marrow infiltrate, suspected myeloproliferative, myelodysplastic, or lymphoproliferative processes, and immune disorders.

• Indications for hemogram or CBC related to red cell (RBC) parameters of the hemogram include signs, symptoms, test results, illness, or disease that can be associated with anemia or other red blood cell disorder (e.g., pallor, weakness, fatigue, weight loss, bleeding, acute injury associated with blood loss or suspected blood loss, abnormal menstrual bleeding, hematuria, hematemesis, hematochezia, positive fecal occult blood test, malnutrition, vitamin deficiency, malabsorption, neuropathy, known malignancy, presence of acute or chronic disease that may have associated anemia, coagulation or hemostatic disorders, postural dizziness, syncope, abdominal pain, change in bowel habits, chronic marrow hypoplasia or decreased RBC production, tachycardia, systolic heart murmur, congestive heart failure, dyspnea, angina, nailbed deformities, growth retardation, jaundice, hepatomegaly, splenomegaly, lymphadenopathy, ulcers on the lower extremities).

• Indications for hemogram or CBC related to red cell (RBC) parameters of the hemogram include signs, symptoms, test results, illness, or disease that can be associated with polycythemia (for example, fever, chills, ruddy skin, conjunctival redness, cough, wheezing, cyanosis, clubbing of the fingers, orthopnea, heart murmur, headache, vague cognitive changes including memory changes, sleep apnea, weakness, pruritus, dizziness, excessive sweating, visual symptoms, weight loss, massive obesity, gastrointestinal bleeding, paresthesias, dyspnea, joint symptoms, epigastric distress, pain and erythema of the fingers or toes, venous or arterial thrombosis, thromboembolism, myocardial infarction, stroke, transient ischemic attacks, congenital heart disease, chronic obstructive pulmonary disease, increased erythropoietin production associated with neoplastic, renal or hepatic disorders, androgen or diuretic use, splenomegaly, hepatomegaly, diastolic hypertension.)

• Specific indications for CBC with differential count related to the WBC include signs, symptoms, test results, illness, or disease associated with leukemia, infections or inflammatory processes, suspected bone marrow failure or bone marrow infiltrate, suspected myeloproliferative, myelodysplastic or lymphoproliferative disorder, use of drugs that may cause leukopenia, and immune disorders (e.g., fever, chills, sweats, shock, fatigue, malaise, tachycardia, tachypnea, heart murmur, seizures, alterations of consciousness, meningismus, pain such as headache, abdominal pain, arthralgia, odynophagia, or dysuria, redness or swelling of skin, soft tissue bone, or joint, ulcers of the skin or mucous membranes, gangrene, mucous membrane discharge, bleeding, thrombosis, respiratory failure, pulmonary infiltrate, jaundice, diarrhea, vomiting, hepatomegaly, splenomegaly, lymphadenopathy, opportunistic infection such as oral candidiasis.)

• Specific indications for CBC related to the platelet count include signs, symptoms, test results, illness, or disease associated with increased or decreased platelet production and destruction, or platelet dysfunction(e.g., gastrointestinal bleeding, genitourinary tract bleeding, bilateral epistaxis, thrombosis, ecchymosis, purpura, jaundice, petechiae, fever, heparin therapy, suspected DIC, shock, pre-eclampsia, neonate with maternal ITP, massive transfusion, recent platelet transfusion, cardiopulmonary bypass, hemolytic uremic syndrome, renal diseases, lymphadenopathy, hepatomegaly, splenomegaly, hypersplenism, neurologic abnormalities, viral or other infection, myeloproliferative, myelodysplastic, or lymphoproliferative disorder, thrombosis, exposure to toxic agents, excessive alcohol ingestion, autoimmune disorders (SLE, RA and other).

• Indications for hemogram or CBC related to red cell (RBC) parameters of the hemogram include, in addition to those already listed, thalassemia, suspected hemoglobinopathy, lead poisoning, arsenic poisoning, and spherocytosis.

• Specific indications for CBC with differential count related to the WBC include, in addition to those already listed, storage diseases/mucopolysaccharidoses, and use of drugs that cause leukocytosis such as G-CSF or GM-CSF.

• Specific indications for CBC related to platelet count include, in addition to those already listed, May-Hegglin syndrome and Wiskott-Aldrich syndrome.

Limitations

• Testing of patients who are asymptomatic, or who do not have a condition that could be expected to result in a hematological abnormality, is screening and is not a covered service.

• In some circumstances it may be appropriate to perform only a hemoglobin or hematocrit to assess the oxygen carrying capacity of the blood. When the ordering provider requests only a hemoglobin or hematocrit, the remaining components of the CBC are not covered.

• When a blood count is performed for an end-stage renal disease (ESRD) patient, and is billed outside the ESRD rate, documentation of the medical necessity for the blood count must be submitted with the claim.

• In some patients presenting with certain signs, symptoms or diseases, a single CBC may be appropriate. Repeat testing may not be indicated unless abnormal results are found, or unless there is a change in clinical condition. If repeat testing is performed, a more descriptive diagnosis code (e.g., anemia) should be reported to support medical necessity. However, repeat testing may be indicated where results are normal in patients with conditions where there is a continued risk for the development of hematologic abnormality.

Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).

Text reproduced from the CMS Medicare Coverage Database record for NCD 190.15 version 1. View the original on cms.gov.

Laboratory NCD code lists (October 2026)

Medicare contractors apply this NCD through a national edit: the procedure codes below are paid only when the claim carries a covered diagnosis. The October 2026 list works by exclusion: any ICD-10-CM code that is not on it supports medical necessity. It names 22,258 codes that do not support medical necessity and 233 non-covered codes that deny.

11 procedure codes are edited against this NCD's diagnosis list. CPT codes are shown as numbers only; descriptors are licensed by the AMA.

Procedure codes subject to NCD 190.15
CodeCode set
85004CPT (descriptor licensed by AMA)
85007CPT (descriptor licensed by AMA)
85008CPT (descriptor licensed by AMA)
85013CPT (descriptor licensed by AMA)
85014CPT (descriptor licensed by AMA)
85018CPT (descriptor licensed by AMA)
85025CPT (descriptor licensed by AMA)
85027CPT (descriptor licensed by AMA)
85032CPT (descriptor licensed by AMA)
85048CPT (descriptor licensed by AMA)
85049CPT (descriptor licensed by AMA)

What Medicare pays for these tests: 11 of the 11 codes carry a national payment amount on the October 2026 Clinical Laboratory Fee Schedule, from $2.37 to $7.77, with no deductible or coinsurance. QW marks the CLIA-waived variant of a test.

Clinical Laboratory Fee Schedule amounts for the codes NCD 190.15 edits, October 2026
CodeCLFS amountWith QWPricing
85004$6.47—national payment amount
85007$3.80—national payment amount
85008$3.43—national payment amount
85013$7.00—national payment amount
85014$2.37$2.37national payment amount
85018$2.37$2.37national payment amount
85025$7.77$7.77national payment amount
85027$6.47—national payment amount
85032$4.31—national payment amount
85048$2.54—national payment amount
85049$4.48—national payment amount
Source: CMS Clinical Laboratory Fee Schedule 26CLABQ4. Every code range and the October changes are on the Clinical Laboratory Fee Schedule page.

22,258 diagnosis codes on the list do not support medical necessity under this NCD; the first 20 are shown with FY2027 ICD-10-CM descriptions.

ICD-10-CM codes that do not support medical necessity for NCD 190.15 (sample)
ICD-10-CMDescriptionEffective
A18.59Other tuberculosis of eye2015-10-01
A63.0Anogenital (venereal) warts2015-10-01
B07.0Plantar wart2015-10-01
B07.8Other viral warts2015-10-01
B07.9Viral wart, unspecified2015-10-01
D00.00Carcinoma in situ of oral cavity, unspecified site2015-10-01
D00.01Carcinoma in situ of labial mucosa and vermilion border2015-10-01
D00.02Carcinoma in situ of buccal mucosa2015-10-01
D00.03Carcinoma in situ of gingiva and edentulous alveolar ridge2015-10-01
D00.04Carcinoma in situ of soft palate2015-10-01
D00.05Carcinoma in situ of hard palate2015-10-01
D00.06Carcinoma in situ of floor of mouth2015-10-01
D00.07Carcinoma in situ of tongue2015-10-01
D00.08Carcinoma in situ of pharynx2015-10-01
D04.0Carcinoma in situ of skin of lip2015-10-01
D04.10Carcinoma in situ of skin of unspecified eyelid, including canthus2015-10-01
D04.111Carcinoma in situ of skin of right upper eyelid, including canthus2018-10-01
D04.112Carcinoma in situ of skin of right lower eyelid, including canthus2018-10-01
D04.121Carcinoma in situ of skin of left upper eyelid, including canthus2018-10-01
D04.122Carcinoma in situ of skin of left lower eyelid, including canthus2018-10-01

233 diagnosis codes deny automatically under this NCD; the first 20 are shown.

Non-covered ICD-10-CM codes for NCD 190.15 (sample)
ICD-10-CMDescription
R99Ill-defined and unknown cause of mortality
Z00.00Encounter for general adult medical examination without abnormal findings
Z00.01Encounter for general adult medical examination with abnormal findings
Z00.110Health examination for newborn under 8 days old
Z00.111Health examination for newborn 8 to 28 days old
Z00.121Encounter for routine child health examination with abnormal findings
Z00.129Encounter for routine child health examination without abnormal findings
Z00.5Encounter for examination of potential donor of organ and tissue
Z00.6Encounter for examination for normal comparison and control in clinical research program
Z00.70Encounter for examination for period of delayed growth in childhood without abnormal findings
Z00.71Encounter for examination for period of delayed growth in childhood with abnormal findings
Z00.8Encounter for other general examination
Z02.0Encounter for examination for admission to educational institution
Z02.1Encounter for pre-employment examination
Z02.2Encounter for examination for admission to residential institution
Z02.3Encounter for examination for recruitment to armed forces
Z02.4Encounter for examination for driving license
Z02.5Encounter for examination for participation in sport
Z02.6Encounter for examination for insurance purposes
Z02.71Encounter for disability determination

Changed in October 2026

The October 2026 lab NCD release changed this NCD's ICD-10-CM list: 3 codes added and 7 codes removed against January 2026. CMS marked 3 rows of the list as changed in this release. A removed code stops counting for the edit after its term date; where the FY2027 ICD-10-CM update deleted the code, the replacement codes listed below are the ones to report from October 1, 2026.

ICD-10-CM codes added to NCD 190.15 in October 2026
ICD-10-CMFY2027 descriptionResult
M72.20Plantar fascial fibromatosis, unspecified footdoes not support medical necessity
M72.21Plantar fascial fibromatosis, right footdoes not support medical necessity
M72.22Plantar fascial fibromatosis, left footdoes not support medical necessity
ICD-10-CM codes removed from NCD 190.15 in October 2026
ICD-10-CMDescriptionWasWhy
M72.2Plantar fascial fibromatosisdoes not support medical necessitydeleted from ICD-10-CM; replaced by M67.A01, M67.A02, M67.A09, M72.20, M72.21, M72.22
S23.420ASprain of sternoclavicular (joint) (ligament), initial encounterdoes not support medical necessitydeleted from ICD-10-CM; replaced by no listed code
S23.420SSprain of sternoclavicular (joint) (ligament), sequeladoes not support medical necessitydeleted from ICD-10-CM; replaced by no listed code
T52.8X1SToxic effect of other organic solvents, accidental (unintentional), sequeladoes not support medical necessitydeleted from ICD-10-CM; replaced by T52.811S, T52.821S, T52.891S
T52.8X2SToxic effect of other organic solvents, intentional self-harm, sequeladoes not support medical necessitydeleted from ICD-10-CM; replaced by T52.812S, T52.822S, T52.892S
T52.8X3SToxic effect of other organic solvents, assault, sequeladoes not support medical necessitydeleted from ICD-10-CM; replaced by T52.813S, T52.823S, T52.893S
T52.8X4SToxic effect of other organic solvents, undetermined, sequeladoes not support medical necessitydeleted from ICD-10-CM; replaced by T52.814S, T52.824S, T52.894S

Codes on this NCD's list by release: October 2025: 22,394 · January 2026: 22,495 · October 2026: 22,491. Every change across the 23 laboratory NCDs is in the lab NCD code-list change report.

Revision history

12/2019 - Changes to the Laboratory National Coverage Determination (NCD) Edit Software for April 2020. This Change Request (CR) announces the changes that will be included in the April 2020 quarterly release of the edit module for clinical diagnostic laboratory services. This recurring update notification applies to chapter 16, section 120.2, publication 100-04. ( TN 4475 ) (CR11593)

07/2004 - Published NCD in the NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance now published in Medicare Lab NCD Manual. Effective and Implementation dates NA. ( TN 17 ) (CR 2130)

07/2002 - Implemented NCD. Effective date 11/25/02. Implementation date 1/01/03. ( TN AB-02-110 ) (CR 2130)

How this NCD shows up on remittances

A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.

For teams evaluating QuickIntell software

Evaluate a coverage-review workflow around NCD 190.15

Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — NCD 190.15

What does NCD 190.15 cover?

Indications for a CBC or hemogram include red cell, platelet, and white cell disorders. Examples of these indications are enumerated individually below. The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.

When did NCD 190.15 take effect?

The current version (1) is effective 11/25/2002, implemented 01/01/2003, published in transmittal 17. This is the only published version.

Does a Local Coverage Determination override NCD 190.15?

No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).

Which diagnosis codes are covered under NCD 190.15?

The October 2026 laboratory NCD edit list for blood counts works by exclusion: any ICD-10-CM code that is not on the list supports medical necessity. It lists 22,258 codes that do not support medical necessity (for example A18.59 Other tuberculosis of eye; A63.0 Anogenital (venereal) warts; B07.0 Plantar wart) and 233 codes that deny. The list applies to 85004, 85007, 85008, 85013, 85014, 85018 and others.

How often does the lab NCD code list for 190.15 change?

CMS updates the laboratory NCD edit module quarterly, with the October release carrying the annual ICD-10-CM code changes. Codes added or deleted mid-year appear in the quarterly change spreadsheets on the Lab NCDs page.

CMS guidance

Medicare Learning Network publications that CMS issues on this topic, cited by ICN and publication date:

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.